Skip to main content
Loading

Navega Therapeutics

Monday, February 26, 2024
Plymouth
Gene/Cell Therapy
Navega Therapeutics' mission is to develop durable relief for chronic and complex diseases, via DNA gene regulation. The company’s technology is centered around a ZF-AI, a proprietary deep learning algorithm exclusively in-licensed from UCSD that enables the design of zinc-finger protein arrays to target DNA of any length without the need of linkers, to enable epigenetic gene therapies--or the ability to up and down regulate genes of interest with high level of specificity and potency at the DNA level. As Navega not only believes that epigenetic modulators are of importance, but also how these are delivered, the company also has unique IP around immune-stealth AAVs that enable dosing even if pre-existing antibodies exist, as well as circular-RNA technology which enables epigenetic modulation via lipid nanoparticle delivery. The company has three programs, in chronic pain, rheumatoid arthritis, and retinitis pigmentosa with IND expected by Q12025.
Speakers
Ana Moreno, CEO - Navega Therapeutics

State

California

Country

United States

Website

http://www.navegatx.com

CEO/Top Company Official

Ana Moreno

Lead Product in Development

AAV epigenetic gene therapy targeting Nav1.7 showing the ability to prevent and reverse chronic pain in multiple pain models (inflammatory, neuropathic, visceral, arthritic pain), with IND expected in Q12025.

Development Phase of Primary Product

Pre-Clinical
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP